Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults

WALTHAM - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. , today announced that XACDURO is now available in the United States for patients 18 years of age and older for the...

Related Keywords

United States ,Pavel Raifeld ,Margaret Koziel ,Drug Administration ,Innoviva Inc ,Securities Exchange ,Jolla Pharmaceutical Company ,Entasis Therapeutics Inc ,Centers For Disease ,Glaxo Group Limited ,Innoviva Specialty Therapeutics Inc ,Exchange Commission ,World Health Organization ,Nasdaq ,Specialty Therapeutics ,Chief Executive Officer ,Innoviva Specialty ,Infectious Disease ,Chief Medical Officer ,Disease Control ,Health Organization ,Specialty Therapeutic ,Therapeutics Inc ,Innoviva Specialty Therapeutics ,Group Limited ,Long Acting Beta ,Collaboration Agreement ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Risk Factor ,Financial Condition ,Annual Report ,Quarterly Reports ,News Publishing ,Markets ,